1,872 research outputs found

    Acknowledgements

    Get PDF

    Título: Olim felicis recordationis Sixtus V.

    Get PDF
    Precede al tít. : "Ad perpetuam rei memoriam"Tít. y autor tomados de comienzo de textoTexto fechado en Roma el día 3 de noviembre de 1637Sign. : A5Inicial grab. xi

    Título: Declaratio quad per alienationem

    Get PDF
    Sign. : A4Port. con esc. papal xi

    Título: Dilecto filio nostro Paulo

    Get PDF
    A comienzo de texto esc. xil. papalesPie de imp. tomado de colofónInicial grab. xilSign. : A

    [Ilíada. Inglés]

    Get PDF
    Sign.: A5, B-C8, D

    Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19 : the CARE – COALITION VIII randomised clinical trial

    Get PDF
    Background: COVID-19 progression is associated with an increased risk of arterial and venous thrombosis. Randomised trials have demonstrated that anticoagulants reduce the risk of thromboembolism in hospitalised patients with COVID-19, but a benefit of routine anticoagulation has not been demonstrated in the outpatient setting. Methods: We conducted a randomised, open-label, controlled, multicentre study, evaluating the use of rivaroxaban in mild or moderate COVID-19 patients. Adults ≥18 years old, with probable or confirmed SARS-CoV-2 infection, presenting within ≤7 days from symptom onset with no clear indication for hospitalization, plus at least 2 risk factors for complication, were randomised 1:1 either to rivaroxaban 10 mg OD for 14 days or to routine care. The primary efficacy endpoint was the composite of venous thromboembolic events, need of mechanical ventilation, acute myocardial infarction, stroke, acute limb ischemia, or death due to COVID-19 during the first 30 days. ClinicalTrials.gov: NCT04757857. Findings: Enrollment was prematurely stopped due to sustained reduction in new COVID-19 cases. From September 29th, 2020, through May 23rd, 2022, 660 patients were randomised (median age 61 [Q1-Q3 47–69], 55.7% women). There was no significant difference between rivaroxaban and control in the primary efficacy endpoint (4.3% [14/327] vs 5.8% [19/330], RR 0.74; 95% CI: 0.38–1.46). There was no major bleeding in the control group and 1 in the rivaroxaban group. Interpretation: On light of these findings no decision can be made about the utility of rivaroxaban to improve outcomes in outpatients with COVID-19. Metanalyses data provide no evidence of a benefit of anticoagulant prophylaxis in outpatients with COVID-19. These findings were the result of an underpowered study, therefore should be interpreted with caution

    Recent observations and studies of the middle and upper atmosphere at Syowa Station (39.6E, 69S)

    Get PDF
    第6回極域科学シンポジウム分野横断型セッション:[IM] 横断 中層大気・熱圏11月17日(火) 統計数理研究所 セミナー室2(D304
    corecore